Adrenomed AG announced that it has received approximately €24,200,000 in its equity round of funding led by new investors Wellington Ventures and HBM Healthcare Investments (Cayman) Ltd. on November 23, 2018. The company entered into agreements with several investors and shareholders for the transaction. The transaction included participation from existing investor, Deutsche Biotech Innovativ AG (DUSE:VUA) and other investors. Post-closing of the transaction, Deutsche Biotech Innovativ AG (DUSE:VUA) stake in the company reduced from 19.7% to 12.8%.